Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 August 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Alistair Naidoo, second-year master’s student in Conservation Genetics and full-time technician in the Department of Genetics; Prof Paul Grobler, Head of the Department of Genetics; Prof Gordon Luikart; and Hannah Janse van Vuuren, third-year master’s student in Conservation Genetics.

It is an important and exciting time to be doing research in conservation genetics. This is according to Prof Gordon Luikart, Professor of Conservation Ecology and Genetics at the Flathead Lake Bio Station at the University of Montana in the United States. 

Prof Luikart, whose primary research focus is the application of genetics to the conservation of natural and managed populations, recently delivered a lecture, The Expanding Role of Genetics/omics in Wildlife Research and Conservation, on the Bloemfontein Campus of the University of the Free State (UFS). The lecture, hosted by the Department of Genetics, was attended by a group of students and lecturers in conservation and a number of related fields. 

He is one of the leading scientists in the field of conservation genetics, including integration of genomics in conservation projects. He is also co-author of the textbook Conservation and the Genomics of populations – the current prescribed textbook for GENE3744.

Species threatened with extinction

In 2008, the International Union for Conservation of Nature (IUCN) stated that approximately 10-20% of all vertebrate and plant species are threatened with extinction over the next few decades. In 1984, American biologist Edward O Wilson also said that it will take millions of years to correct the ongoing loss of genetics and species diversity caused by the destruction of natural habitats. “This is the folly our descendants are least likely to forgive us.”

Prof Luikart is of the opinion that genetics has enormous potential to help manage wildlife and prevent extirpation. “My research works to realise this potential and help wildlife managers conserve populations and ecosystems,” he says. 

Conservation managers and biologists have understood the risks of inbreeding for more than 100 years. In his lecture, one of the aspects of genetic conservation he focused on, was the negative effects of inbreeding and how this can be reversed using genetic rescue. 

With the genetic rescue study, they found that the gene flow into recently isolated populations can increase individual fitness and population growth. He proposed that conservation managers should consider genetic principles and rescue as practical and important tools. 

Prof Luikart also provided a list of information that can be retrieved from molecular genetic data to help conservation managers. This includes intel on census and effective population size, gene flow and dispersal, local adaptation and selection, forensics, genetic identification and law enforcement, and disease ecology and transmission. 

Non-invasive genetic monitoring

In terms of detecting gene flow, he focused on a study about non-invasive genetic monitoring that was conducted in the Yellowstone Park. Prof Luikart and a group of students collected the shed hair and faeces of the grizzly bear, obtained from trees and hair traps, which were used as a source of DNA. 

They established, for instance, that inbreeding depression is more common and stronger than previously thought in natural populations. Genetic monitoring, using non-invasive methods as described, has been found to be an effective tool that conservation managers should consider for detecting inbreeding and loss of genome-wide variation.

His research on the bighorn sheep, the alpine ibex, and the black bear informed most of the findings he discussed during his lecture.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept